Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
OTCBB:KDUS's Cash to Debt is ranked higher than
85% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. OTCBB:KDUS: No Debt )
OTCBB:KDUS' s 10-Year Cash to Debt Range
Min: 241.08   Max: No Debt
Current: No Debt

Interest Coverage No Debt
OTCBB:KDUS's Interest Coverage is ranked higher than
97% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OTCBB:KDUS: No Debt )
OTCBB:KDUS' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 254.69
M-Score: -3.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -2.37
OTCBB:KDUS's ROE (%) is ranked higher than
83% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. OTCBB:KDUS: -2.37 )
OTCBB:KDUS' s 10-Year ROE (%) Range
Min: -105.12   Max: 108.95
Current: -2.37

-105.12
108.95
ROA (%) -2.35
OTCBB:KDUS's ROA (%) is ranked higher than
83% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. OTCBB:KDUS: -2.35 )
OTCBB:KDUS' s 10-Year ROA (%) Range
Min: -75.33   Max: 68.89
Current: -2.35

-75.33
68.89
ROC (Joel Greenblatt) (%) -4.38
OTCBB:KDUS's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. OTCBB:KDUS: -4.38 )
OTCBB:KDUS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -70800   Max: -5.3
Current: -4.38

-70800
-5.3
EBITDA Growth (3Y)(%) 10.10
OTCBB:KDUS's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. OTCBB:KDUS: 10.10 )
OTCBB:KDUS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -76.2   Max: 48.7
Current: 10.1

-76.2
48.7
» OTCBB:KDUS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OTCBB:KDUS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.00
KDUS's P/B is ranked higher than
97% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. KDUS: 1.00 )
KDUS' s 10-Year P/B Range
Min: 0.61   Max: 1.1
Current: 1

0.61
1.1
Current Ratio 494.99
KDUS's Current Ratio is ranked higher than
100% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. KDUS: 494.99 )
KDUS' s 10-Year Current Ratio Range
Min: 5.51   Max: 24108
Current: 494.99

5.51
24108
Quick Ratio 494.99
KDUS's Quick Ratio is ranked higher than
100% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. KDUS: 494.99 )
KDUS' s 10-Year Quick Ratio Range
Min: 5.51   Max: 24108
Current: 494.99

5.51
24108

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.50
KDUS's Price/Net Cash is ranked higher than
96% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. KDUS: 2.50 )
KDUS' s 10-Year Price/Net Cash Range
Min: 0.39   Max: 2.57
Current: 2.5

0.39
2.57
Price/Net Current Asset Value 2.50
KDUS's Price/Net Current Asset Value is ranked higher than
96% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. KDUS: 2.50 )
KDUS' s 10-Year Price/Net Current Asset Value Range
Min: 0.39   Max: 2.55
Current: 2.5

0.39
2.55
Price/Tangible Book 0.90
KDUS's Price/Tangible Book is ranked higher than
99% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. KDUS: 0.90 )
KDUS' s 10-Year Price/Tangible Book Range
Min: 0.33   Max: 4
Current: 0.9

0.33
4
Price/DCF (Projected) 1.10
KDUS's Price/DCF (Projected) is ranked higher than
99% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. KDUS: 1.10 )
KDUS' s 10-Year Price/DCF (Projected) Range
Min: 0.89   Max: 2.04
Current: 1.1

0.89
2.04
Earnings Yield (Greenblatt) -3.30
KDUS's Earnings Yield (Greenblatt) is ranked higher than
75% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. KDUS: -3.30 )
KDUS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -3.3   Max: 1103.3
Current: -3.3

-3.3
1103.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Cadus Corporation was incorporated under the laws of the State of Delaware in January 1992 and until July 30, 1999 devoted all of its resources to the development and application of novel yeast-based and other drug discovery technologies. The Company has a wholly owned subsidiary, Cadus Technologies, Inc., which holds all patents, patent applications, know how, licenses and drug discovery technologies of the Company. The Company has developed technologies based on yeast that are useful in identifying drug discovery candidates targeted at G Protein-coupled receptors. Yeast is a single-celled microorganism that is commonly used to make bread, beer and wine. The Company has developed several proprietary drug discovery technologies that address many of the limitations of traditional drug discovery methods, including tools used to screen for compounds that act as agonists or antagonists to cell surface receptors and tools used to identify ligands to targeted orphan receptors. The Company developed a proprietary technology to insert human genes into yeast cells to create hybrid yeast cells. The Company's scientists typically created hybrid yeast cells by replacing yeast G Protein-coupled receptor genes and certain signaling molecules with their human equivalents. As a result, these hybrid yeast cells express a human G Protein-coupled receptor and a portion of its signaling pathway. The Company designed and developed more than twenty-five thousand genetically different yeast strains that could be used to build novel hybrid yeast cells. The Yeast System provides a facile means of identifying molecules that alter the activity of G protein coupled receptors through high throughput screening. The Yeast System also provides a procedure for identifying natural and artificial ligands for orphan G protein coupled receptors, i.e., proteins predicted to be GPCRs. The biotechnology and pharmaceutical industries are competitive. The Company main competitor is Glaxo Smith Kline, Plc, which might use yeast as a drug discovery medium.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK